Proton Pump Inhibitors and Risk of Drug Interactions

S.M. Tkach, L.A. Onishchuk

Abstract


In the article, the current data regarding drug interactions of proton pomp inhibitors (PPI) with other preparations are discussed. It is concluded that the risk of adverse drug interactions is enhanced by the use of PPIs and drugs primarily metabolized by cytochrome isoenzyme CYP2C19. If the simultaneous application of IPP with many other drugs, including clopidogrel, is necessary, the preference should be given to pantoprazole.


Keywords


proton pomp inhibitors; drug interactions; cytochrome P450 system; pantoprazole

References


Abraham N.S., Hlatky M.A., Antman E.M. et al. ACCF/ACG/AHA-2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA-2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A report of the American college of cardiology foundation task force on expert consensus documents // J. Am. Coll. Cardiol. — 2010. — 56 (24). — 2051-2066.

Banerjee S., Weideman R.A., Weideman M.W. et al. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention // Am. J. Cardiol. — 2011. — 107. — 871-878.

Bekkers C.H., Touw D.J., Lamers C.B., Geus W.P. The effect of CYP2C19 polymorphism on the pharmacokinetics and acid-inhibitory effects of oral lansoprazole and omeprazole // Br. J. Clin. Pharmacol. — 2002. — 54 (5). — 553.

Bhatt D.L., Cryer B.L., Contant C.F. et al. Clopidogrel with or without omeprazole in coronary artery disease // N. Engl. J. Med. — 2010. — 363 (20). — 1909-1917.

Bhatt D.L., Scheiman J., Abraham N.S. et al. ACCF/ACG/AHA-2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use // Am. J. Gastroenterol. — 2008. — 103. — 2890-2907.

Desta Z., Zhao X., Shin J.G., Flockhart D.A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism // Clin. Pharmacokinet. — 2002. — 41. — 913-958.

Egan L.J. Mechanisms of Drug Toxicity or Intolerance // Dig. Dis. — 2011. — 29. — 172-176

FDA reminder to avoid concomitant use of Plavix (clopidogrel) and omeprazole. — www.fda.gov/Drugs/DrugSafety/ucm231161. htm

Fitton A., Wiseman L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders // Drugs. — 1996. — 51 (3). — 460-482.

Furuta T., Shirai N., Sugimoto M., Nakamura A., Hishida A., Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies // Drug Metab. Pharmacokinet. — 2005. — 20 (3). — 53-167.

Furuta T., Sugimoto M., Shirai N., Ishizaki T. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor // Pharmacogenomics. — 2007. — 8. — 1199-1210.

Gardiner S.J., Begg E.J. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice // Pharmacol. Rev. — 2006. — 58 (3). — 521-590.

Gerson L.B., Triadafilopoulos G. Proton pump inhibitors and their drug interactions: an evidence-based approach // Eur. J. Gastroenterol. Hepatol. — 2001. — 13 (5). — 611-616.

Gilard M., Arnaud B., Cornily J.C. et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study // J. Am. Coll. Cardiol. — 2008. — 51. — 256-260.

Hagymási K., Müllner K., Herszényi L., Tulassay Z. Update on the pharmacogenomics of proton pump inhibitors // Pharmacogenomics. — 2011. — 12 (6). — 873-888.

Hunfeld N.G., Mathot R.A., Touw D.J., van Schaik R.H., Mulder P.G., Franck P.F., Kuipers E.J., Geus W.P. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians // Br. J. Clin. Pharmacol. — 2008. — 65. — 752-760.

Johnson D.A. Concomitant use of PPIs and antiplatelet therapy // Gastroenterol. Hepatol. — 2011. — 7. — 7-10.

Juhasz M., Herszenyi L., Tulassay Z.S. Current standings of the proton pump inhibitor and clopidrogel co-therapy: review on an evolving field with the eyes of the gastroenterologist // Digestion. — 2010. — 81 (1). — 10-15.

Kazui M., Nishiya Y., Ishizuka T. et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite // Drug Metab. Dispos. — 2010. — 38. — 92-99.

Kromer W. Similarities and Differences in the Properties of Substituted Benzimidazoles: A Comparison detween Pantoprazole and Related Compounds // Digestion. — 1995. — 56. — 443-454.

Kwok C.S., Jeevanantham V., Dawn B. et al. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis // Int. J. Cardiol. — 2012 Mar 29. Epub ahead of print.

Kwok C.S., Loke Y.K. Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a syste-matic review // Drug Saf. — 2012. — 35. — 127-139.

Laine L., Hennekens C. Proton pump inhibitor and clopidrogel interaction: fact or fiction? // Am. J. Gastroente­rol. — 2010. — 105 (1). — 34-41.

Lee K.C., Ma J.D., Kuo G.M. Pharmacogenomics: bridging the gap between science and practice // J. Am. Pharm. Assoc. — 2010. — 50 (1). — e1-e17.

Li X.-Q., Andersson T.B., Ahlstrom M., Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities // Drug Metab. Dis. — 2004. — 32 (8). — 821-827.

Mullin J.M., Gabello M., Murray L.J. et al. Proton pump inhbitors: actions and reactions // Drug Disc. Today. — 2009. — 14 (13-14). — 647-660.

Ogawa R., Echizen H. Drug-drug interaction profiles of proton pump inhibitors // Clin. Pharmacokinet. — 2010. — 49 (8). — 509-533.

Ray W.A., Murray K.T., Griffin M.R. et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study // Ann. Intern. Med. — 2010. — 152. — 337-345.

Robinson M., Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know // Drugs. — 2003. — 63 (24). — 2739-2754.

Sachs G., Shin J. Differential reversal of inhibition of gastric H/K-ATPase following pantoprazole or omeprazole administration // Am. J. Gzstroenterol. — 2001. — 96. — S71.Abstr.223

Sakai T., Aoyama N., Kita T. et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects // Pharm. Res. — 2001. — 18 (6). — 721-727.

Shin J.M., Sachs G. Pharmacology of proton pump inhibitors // Curr. Gastroenterol. Rep. — 2008. — 10 (6). — 528-534.

Steinijans V., Huber R., Hartmann M. et al. Lack of pantoprazole drug interactions in man: an updated review // Int. J. Clin. Pharmacol. Ther. — 1996. — 34 (1 Suppl.). — S31-S50.

Southworth M.R., Temple R. Interaction of clopidogrel and omeprazole // N. Engl. J. Med. — 2010. — 363 (20). — 1977.

Tanaka M., Ohkubo T., Otani K. et al. Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin // Clin. Pharmacol. Ther. — 2001. — 69 (3). — 108-113.

Trifiro G., Corrao S., Alacqua M. et al. Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources // Br. J. Clin. Pharmacol. — 2006. — 62 (5). — 582-590.

Tucker G. The interaction of proton pump inhibitors with the cytochromes P450 // Aliment. Pharmacol. Ther. — 1994. — 8. — 33-38

Van Boxel O.S., van Oijen M.G., Hagenaars M.P. et al. Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study // Am. J. Gastroenterol. — 2010. — 105. — 2430-2436. — quiz, 2437.

Volpe M., Chin D., Paneni F. The challenge of polypharmacy in cardiovascular medicine // Fundam. Clin. Pharmacol. — 2010. — 24. — 9-17.

Zanger U.M., Turpeinen M., Klein K., Scwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation // Anal. Bioanal. Chem. — 2008. — 392 (6). — 1093-1108.




DOI: https://doi.org/10.22141/2308-2097.2.56.2015.81503

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru